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Abstract
Introduction: In high multidrug resistant (MDR) tuberculosis (TB) prevalence areas, drug susceptibility testing (DST) at
diagnosis is recommended for patients with risk factors for MDR. However, this approach might miss a substantial
proportion of MDR-TB in the general population. We studied primary MDR in patients considered to be at low risk of MDR-
TB in Lima, Peru.
Methods: We enrolled new sputum smear-positive TB patients who did not report any MDR-TB risk factor: known exposure
to a TB patient whose treatment failed or who died or who was known to have MDR-TB; immunosuppressive co-morbidities,
ex prison inmates; prison and health care workers; and alcohol or drug abuse. A structured questionnaire was applied to all
enrolled participants to confirm the absence of these factors and thus minimize underreporting. Sputum from all
participants was cultured on Lo¨wenstein-Jensen media and DST for first line drugs was performed using the 7H10 agar
method.
Results: Of 875 participants with complete data, 23.2% (203) had risk factors for MDR-TB elicited after enrolment. Among
the group with no reported risk factors who had a positive culture, we found a 6.3% (95%CI 4.4–8.3) (37/584) rate of MDR-
TB. In this group no epidemiological characteristics were associated with MDR-TB. Thus, in this group, multidrug resistance
occurred in patients with no identifiable risk factors.
Conclusions: We found a high rate of primary MDR-TB in a general population with no identifiable risk factors for MDR-TB.
This suggests that in a high endemic area targeting patients for MDR-TB based on the presence of risk factors is an
insufficient intervention.
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Introduction
Drug resistant (DR) tuberculosis (TB) rates are increasing
globally. Access to culture and drug susceptibility tests (DST) for
diagnosis remains unavailable in many settings [1,2]. Tailored case
detection strategies for DR TB are required to maximize
diagnostic efficiency and the rational use of financial, human
and infrastructure resources. The objective of this approach is
early detection of DR patients which in turn should allow early
initiation of appropriate TB treatment regimens with prevention of
clinical deterioration and reduction of transmission of DR strains.
Current international guidelines strongly recommend testing for
DR in specific cases such as TB treatment failure, exposure to a
multidrug resistant (MDR) case, return after default, relapse, in the
presence of a co-morbidity, previous TB treatment with poor
quality drugs or provided by a poor quality programme, and
persistence of a positive smear at month two or three of a standard
short course treatment [3]. In addition, DR testing is recom-
mended in certain populations: HIV-positive patients in areas
where HIV is associated with DR, prisoners, and in persons living
in areas with high DR prevalence [3,4].
In Peru, DST has been centralized for many years in the
national reference laboratory. National surveys from 1996 and
2006 show an increase of MDR rates from 2.4% to 5.3% among
new cases, and from 15.7% to 23.6% in previously treated cases,
respectively [5,6]. MDR rates are heterogeneously distributed
within the country. Urban areas are most affected, with 58% of all
TB cases and 82% of MDR-TB cases reported in Lima [7]. Also
within Lima, a city of 9 million inhabitants, TB and MDR-TB
burden is heterogeneously distributed among the districts. In most
regions, DST is restricted to those with a higher MDR pre test
probability [8]. This targeted testing has shown good results: in
two districts of Lima, 34% of patients with at least one risk factor
for MDR had indeed MDR [9]. A good selection of patients to be
tested based on their pre test probability is a component of an
efficient diagnostic process. In order to contribute with evidence
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for enhanced MDR case detection strategies, we aimed to evaluate
the yield of testing low risk patients living in a high MDR burden
area.
Materials and Methods
Study setting
The study was conducted in a semi-urban district in Lima with a
population over one million inhabitants [10]. The district has a TB
incidence of 213 per 100,000 inhabitants [11] and a MDR
prevalence of 7% among all TB cases in the area [12]. Social
security and private health care facilities also operate in the
district. However, most TB cases are managed in the public health
services [13]. The HIV prevalence in TB patients in this setting is
similar to the national prevalence, which in 2008 was 2.6% [14].
Patient recruitment was conducted in all 34 public health care
facilities (one hospital and 33 first level health care facilities) of the
district. The NTP has designated offices in every facility. Following
national guidelines, TB suspects with at least one sputum sample
positive for acid fast bacilli are started immediately on TB
treatment. Sputum culture and DST for first line drugs are
routinely requested for any retreatment category (failure, return
after default, relapse); persons reporting exposure to a MDR-TB
case or to a TB case that failed treatment or that died during
treatment; patients with immunosuppressive co-morbidities such
as HIV and diabetes; persons working or admitted in a prison;
health care workers, and persons with a recent and prolonged
admission to a hospital [8]. Sputum samples from new TB patients
who do not report one of these high risk factors for MDR are not
cultured routinely. These patients start a regimen for drug
susceptible TB which consists of two months of isoniazid,
rifampicin, ethambutol and pyrazinamide taken six days per week
followed by four months of isoniazid and rifampicin taken two
days per week. During follow-up, patients are evaluated monthly
for smear conversion; if smears remain positive at month two or
three, a sputum sample is sent for culture and DST. A MDR
consultation committee decides further management, usually
starting a standardized second line regimen until full DST results
are available for individualized regimens.
Patient recruitment
From April 2008 to March 2010, adults diagnosed in the 34
health facilities with a first episode of smear positive TB and no
reported risk factors for MDR-TB were eligible and invited to
participate in the study. Trained field workers covered from
Monday to Saturday from 8 am until 2 pm the facilities with large
numbers of TB patients and twice or thrice a week those with
fewer patients. They first screened eligible patients. We considered
risk factors for MDR-TB all the criteria that the national
guidelines use to request a culture and a DST among new smear
positive cases, as well as alcohol and drug abuse. Patients reporting
at least one of these factors were not enrolled. To correct for
underreporting during screening we subsequently looked into
more detail for these risk factors, and previous TB treatment, with
a structured questionnaire applied to every participant enrolled. If
a risk factor was still elicited in enrolled participants, all study
procedures would be continued but these participants would be
excluded in the analysis. Demographic data, exposure to TB, and
clinical data such as use of previous prophylaxis was recorded for
participants. Field workers instructed the patient on submitting a
sputum sample. Patients submitting samples after taking more
than three doses of anti tuberculosis treatment were also excluded.
If the patient had been recently tested for HIV, the result was
retrieved from the clinical files. The NTP recommends and offers
HIV testing to all TB cases. When the patient had not been tested
recently, the field workers offered the patient the option to be
screened. HIV positive patients were referred to the national HIV
programme for management. HAART is provided free of charge
to patients. Pre and post test counselling are done by qualified staff
from the Ministry of Health.
Sample collection and processing
If the patient could not produce a sputum sample on the spot, a
morning sample was collected the next day. Sputa were
transported within six hours to the microbiology laboratory at
the Instituto de Medicina Tropical Alexander von Humboldt.
Samples were kept at room temperature and processed on the day
of arrival. If a sample arrived in the afternoon or on a Saturday, it
was kept at 4uC until the next day or until Monday. A Ziehl-
Neelsen smear was done, and the sputum was cultured in two
slopes of Lo¨wenstein-Jensen media. Positive cultures were tested
for drug susceptibility using the 7H10 agar method and growth
with the following drug concentrations of antibiotics defined
resistance: 0.2 mg/ml isoniazid, 40 mg/ml rifampicin, 6 mg/ml
ethambutol mg and 2 mg/ml streptomycin.
A sample of 74 mycobacterial isolates was sent for external
quality control of DST to the Institute of Tropical Medicine in
Antwerp, Belgium, a WHO/IUATLD supranational reference
laboratory.
Statistical analysis
Data were entered in Microsoft Access database (Microsoft,
Redmond, WA, USA), and analyzed with EpiInfo version 3.5.1
(CDC, Atlanta, GA, USA). A TB patient was the unit of analysis
and the DR pattern the outcome variable. The definition of a
MDR case was resistance to isoniazid and to rifampicin on at least
one Lo¨wenstein-Jensen slope. ‘‘MDR-plus’’ was defined as MDR
and resistance to another drug, ‘‘mono resistance’’ was defined as
resistance to a single drug out of the four tested, ‘‘poly resistance’’
was defined as resistance to at least two drugs not involving the
combination of isoniazid and rifampicin. The MDR rate was the
proportion of MDR-TB cases among the patients that had a DST
result.
Proportions in subgroups were compared using Pearson’s Chi-
square test; odds ratios (OR) were calculated with 95% confidence
intervals (95% CI).
Ethical considerations
This study was approved by the Institutional Ethics Committee
at Universidad Peruana Cayetano Heredia and by the Regional
Health Direction from the Ministry of Health. Written informed
consent was obtained from all participants. All data were
processed anonymously. A separate informed consent was used
if the patient was to be tested for HIV.
Results
We enrolled 909 patients with a first episode of smear positive
pulmonary TB that did not report a high risk factor for MDR-TB
during screening. After thorough questioning, 203 did report at
least one high risk factor for MDR-TB not detected initially and
34 did not give full information. Out of those enrolled but at
known risk for MDR, 198/203 (97.5%) had a culture result
available of which 177/198 (89.4%) were positive. MDR rate
among this group was 13.6% (24/177). None of the participants
with incomplete information on risk factors had MDR-TB. From
the 672 not reporting a risk factor 13.1% (88) were excluded as
they did not have a positive culture. Finally, among participants
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not reporting a risk factor that had a positive culture, 6.3% (95%
confidence intervals (95%CI) 4.4–8.3) (37/584) were MDR.
Enrolment process and MDR rates are shown in figure 1.
Of the isolates sent for DST external quality control, it was
possible to culture 59/74 (79.7%) again. Concordance for
isoniazid and rifampicin resistance profiles was 100% and 93.1%
for ethambutol.
DST patterns for the low risk population are shown in figure 2.
Overall, 117/584 (20.0%, 95%CI 16.8–23.3) were resistant to
isoniazid and among the non MDR patients 80/547 (14.6%, 95%CI
11.7–17.6) were resistant to isoniazid, either mono or poly resistant.
Among the 584 patients at low risk of MDR, 391 were HIV
negative and 193 had an unknown status. The MDR-TB rates in
both groups were similar: 6.7% (95%CI 4.2–9.1) (26/391) and
5.7% (95%CI 2.4–9.0) (11/193), respectively. Table 1 shows the
patient’s characteristics associated with MDR-TB without known
risk factors compared to those with either pan susceptible or with
DR patterns other than MDR. We found no significant factors
associated to MDR. Out of fourteen patients that reported
previous use of isoniazid prophylaxis, none were MDR, six were
resistant to isoniazid (five were mono resistant and one was poly
resistant), and the other eight were pan susceptible.
Discussion
High MDR rates were found among new smear positive
pulmonary TB patients without known risk factors for MDR. This
finding suggests that patients are at risk of infection with a MDR
strain by living in a high incidence area where ongoing
transmission takes place. The high burden of MDR shown in
our data from an urban population may be masked in national
surveillance or in national surveys of drug resistance based on a
representative sample of TB patients in the country, when areas of
low MDR rates predominate. These results should prompt further
investigations in other districts of Lima and regions of Peru. The
course of action derived from this study should be universal access
to DST for populations living in districts with high incidence of
MDR TB.
The study has some limitations. Only patients attending public
sector health care facilities were included. However, in Peru, most
cases of TB are treated within this sector [13]. Also, the selection
of patients without risk factors relied on patient’s report, which
could have masked some risk factors. In particular, patients may
not have reported previous TB treatment which might overesti-
mate the rate of MDR among new cases. To limit under reporting,
once enrolled, exhaustive probing for each factor was done.
Figure 1. Patient enrolment and drug resistance results. Legend: DST=Drug susceptibility test; Drug resistant = any drug resistance, including
MDR; MDR=multidrug resistant.
doi:10.1371/journal.pone.0026276.g001
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Finally, we might have lacked power to detect association with
weak risk factors such as isoniazid prophylaxis. Nevertheless we
have a representative population from a highly populated district
as all public health care facilities were included. The negative
culture results in a group (11%) of enrolled patients might have
been caused by sterilization after taking one or two doses of
Figure 2. DST patterns in patients with no reported risk factors for MDR-TB: rates and confidence intervals. Legend: Mono resistant:
resistance to a single drug out of the four tested; Poly resistant: resistance to at least two drugs not involving the combination of isoniazid and
rifampicin; Only MDR: resistance to isoniazid and rifampicin only; MDR plus: resistance to isoniazid, rifampicin and another drug.
doi:10.1371/journal.pone.0026276.g002
Table 1. Characteristics and MDR status of patients without known risk factors.
Exposure variable MDR Non MDR Crude OR (95% CI)
N n (%) n (%)
Age
Median (IQR) 26.02 (23.16–32.04) 27.52 (22.58–36.56)
,25 226 16 (7.1) 210 (92.9) 1
25–34 197 13 (6.6) 184 (93.4) 1.08 (0.51–2.30)
.35 159 8 (5.0) 151 (95.0) 1.44 (0.60–3.45)
Sex
Male 308 19 (6.2) 289 (93.8)
Female 268 18 (6.7) 250 (93.3) 1?09 (0.56–2.13)
TB contact*
No 337 20 (5.9) 317 (94.1)
Yes 247 16 (6.5) 231 (93.5) 1.09 (0.56–2.16)
Previous prophylaxis
No 535 34 (6.4) 501 (93.6)
Yes 14 0 (0) 14 (100.0) 0.5 (0.003–0.89)**
Tobacco use
No 486 30 (6.2) 456 (93.8)
Yes 79 7 (8.9) 72 (91.1) 1.48 (0.63–3.49)
Residency within the district
Upper area 312 16 (5.1) 297 (94.9)
Lower area 272 21 (7.7) 251 (92.3) 1.55 (0.79–3.04)
*Patient states having been in contact with a person with active TB who is alive and whose episode of TB was not report to be MDR TB.
**To calculate this odds ratio (OR), 0?5 was added to each value, and the standard formulae for OR, confidence intervals and p-value were applied.
doi:10.1371/journal.pone.0026276.t001
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rifampicin, or by a failure in the transport or decontamination
procedures set for the study [15].
The risk factors associated with primary MDR-TB from other
studies cannot be compared to our results as patients with known
risk factors were excluded. We did not find any additional variable
associated with primary MDR-TB. TB treatment failure is the
strongest factor associated to MDR [9,16–19] followed by
exposure to an MDR-TB case or to a case failing treatment.
Female sex has been associated with MDR-TB in some settings
[18,19] as well as lung cavities [20,21].
Enrolled patients with risk factors had a high rate of primary
MDR (13.6%). This rate is most probably underestimated as this
study only enrolled patients with high risk factors that were not
reported during initial screening. The cost effectiveness of testing
all TB cases in high MDR burden areas and only high risk groups
in low risk areas for MDR TB should be evaluated. The feasibility
of testing large numbers of patients, the tests to be used, and the
impact on the efficiency of local, regional and reference
laboratories should also be considered. Introduction of expensive
rapid methods should probably be restricted to settings where their
positive predictive value will be high. Except when extremely
specific, they will yield a high proportion of false positives in areas
with low MDR prevalence and may not be a cost effective as a
screening tool.
The high proportion of primary MDR found among patients
without risk factors attending primary health care facilities in a
populated district in Lima suggests transmission of drug resistant
strains among the general population. This indicates a need for
scaling up strategies to reduce transmission of MDR TB: early
detection, proper management of MDR TB cases, infection
control measures, and addressing the high defaulter rates from
both sensitive and resistant TB. This study suggests that in a high
endemic area targeting patients for DST based on the presence of
risk factors is clearly an insufficient intervention for early case
detection of MDR TB.
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